ClinicalTrialsFinder
RecruitingNot ApplicableNCT04226313

Self-sampling for Non-attenders to Cervical Cancer Screening

Cervical Cancer Prevention Using Self-sampling and Human Papillomavirus Detection

Sponsor

The Institute of Molecular and Translational Medicine, Czech Republic

Enrollment

15,000 participants

Start Date

Sep 23, 2019

Study Type

INTERVENTIONAL

Conditions

Cervical CancerCervical DysplasiaHuman Papillomavirus Infection

Summary

The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.

Eligibility

Sex: FEMALEMin Age: 30 YearsMax Age: 65 Years

Inclusion Criteria5

  • Women with age 30-65 years; for arm A women \> 65 years are allowed
  • Women live in the Czech Republic.
  • Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C).
  • Women with completed informed consent.
  • Women capable of self-sampling of cervicovaginal swab.

Exclusion Criteria3

  • Pregnant women.
  • Women with no sexual intercourse experience.
  • Women after hysterectomy including cervix.

Interventions

DIAGNOSTIC_TESTSelf-sampling by Evalyn Brush

Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.

DIAGNOSTIC_TESTSelf sampling by Evalyn Brush home or in GP´s clinic

Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush

Locations(1)

University Hospital Olomouc

Olomouc, Czechia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04226313

Related Trials

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)

NCT0649866114 locations

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

NCT0697316127 locations

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

NCT049774538 locations

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT0721670360 locations

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180239 locations